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Abstract
Purpose Flunarizine (fz) and cinnarizine (cz) have well-known
extrapyramidal side effects (EPSEs). The aim of this studywas to
evaluate the incidence and occurrence time of cz- and fz-related
EPSEs.
Method Patients who took fz or cz for more than 1 month were
identified from the longitudinal health insurance database 2005
and 2010. Excluded were patients with any of the underlying
diseases that may cause parkinsonism. Drug-induced EPSEs
were defined as the new diagnosis of parkinsonism, dyskinesia,
or secondary dystonia during drug use or within 3 months after
discontinuing the medication. Age- and sex-matched controls
were included in this study.
Results Recruited for analysis were individuals who took fz
(n = 26,133) and cz (n = 7186). The incidence rates of fz- and
cz-induced EPSEs were 21.03 and 10.3 per 10,000
person-months, respectively. The hazard ratios (HRs) of
EPSEs among fz and cz subjects were 8.03 (95% CI 6.55–
9.84) and 3.41 (95% CI 2.50–4.63) when compared with the
control individuals. Both fz and cz patients had a higher cumu-
lative incidence of EPSEs than their control individuals
(p < 0.001). Among subjects who took fz, the incidence of
EPSEswas higher in the second than first year of drug exposure
(45.59 vs 21.03 per 10,000 person-months).
Conclusions Fz and cz significantly increased the risk of par-
kinsonism, dyskinesia, and dystonia. Potential benefits and
risks should be weighed when considering long-term use of
these drugs especially fz.
Keywords Cinnarizine . Flunarizine . Calcium channel
blocker . National Health Insurance ResearchDatabase .




EPSE Extrapyramidal side effect
HR Hazard ratio
DIP Drug-induced parkinsonism
LHID Longitudinal Health Insurance Database
NHIRD National Health Insurance Research Database
ICD-9-
CM
International Classification of Diseases, 9th revi-
sion, clinical modification
CKD Chronic kidney disease
CI Confidence interval
IPD Idiopathic Parkinson’s disease
Introduction
EPSEs are drug-induced movement disorders. These symp-
toms include dystonia (continuous spasms and muscle con-
tractions), akathisia (motor restlessness), parkinsonism
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(characteristic symptoms such as rigidity and slowness of
movement), tremor, and tardive dyskinesia (irregular, jerky
movements). Most patients with drug-induced EPSEs are as-
sociated with lipophilic dopamine D2 receptor blockers pre-
scribed for psychotic disorders and depression [1]. The first
case of fz-induced parkinsonism was reported in 1984 [2].
From that moment, many related cases have been reported
[3–9]. Fz and cz are both calcium channel blockers with a
similar structure and pharmacologic effects. Fz is a
di-fluorinated derivative of cz and has a 2.5–15 time stronger
potency than cz [10]. Other than the calcium entry blocking
effect, fz and cz also have antihistaminic, antiserotoninergic,
and antidopaminergic activities. Because of the D2 receptor
blocking activity [11], both fz and cz have EPSEs including
parkinsonism, orobuccolingual dyskinesia, dystonia, and
akathisia [5, 12]. Previous case series showed that elderly
woman and history of essential tremor may probably be risk
factors for the development of EPSE following cz or fz expo-
sure [4, 5].
Until now, only few studies have used a large sample size to
investigate fz- and cz-induced extrapyramidal symptoms. In
Taiwan, fz and cz are frequently prescribed for vertigo, migraine
prophylaxis, and cerebrovascular blood flow insufficiency. The
aim of this study was to investigate the incidence and occurrence
time of cz- and fz-related EPSEs.
Materials and methods
Data source
This retrospective cohort study used data from the Longitudinal
Health Insurance Databases (LHIDs) 2005 and 2010. Both data-
bases contain registration data and medical claims of 1,000,000
individuals randomly sampled from the 23.68 million beneficia-
ries registered in the National Health Insurance Research
Database (NHIRD). The NHIRD contains a comprehensive
health care information including diagnoses, prescriptions, and
information about inpatient and outpatient care during 1996–
2011. It covers over 99% of the 23 million residents in Taiwan.
This study was approved by the Institutional Review Board of
Chung-Shan Medical University Hospital in Taiwan.
Patient identification
Included in this study were patients who were prescribed cz or fz
from 2002 to 2011 formore than 1month. Patients who had been
prescribed cz or fz in 2001 were excluded. A total of 68,924
patients who took either fz (n = 54,052), cz (n = 13,027), or both
(n = 1665) were identified. The first prescription date of either cz
or fz medication was defined as the index date. Excluded from
the study were 10,961 patients who were diagnosed with one or
more of the several diseases mentioned below before the index
date. They included dementia (International Classification of
Diseases, 9th revision, clinical modification (ICD-9-CM)
290.0∼290.43), neurodegeneration (ICD-9-CM 333.0, 333.4,
334.0–334.9), hydrocephalus (ICD-9-CM331), subdural hemor-
rhage (ICD-9-CM 432.1), brain tumor (ICD-9-CM 191),
Wilson’s disease (ICD-9-CM 275.1), hypoparathyroidism
(ICD-9-CM 252.1, 252.8, 252.9, 275.49A), pantothenate
kinase-associated neurodegeneration (ICD-9-CM 277.9I), hu-
man immunodeficiency virus infection (ICD-9-CM 042,
079.53, 795.71), neurosyphilis (ICD-9-CM 094.89, 094.9), pro-
gressive multifocal leukoencephalopathy (ICD-9-CM 046.3),
toxoplasmosis (ICD-9-CM 130.0, 130.7), and stroke
(ICD-9-CM 431, 432.9, 434, 436). Also excluded were 12,297
patients below the age of 45 and 5728 patients diagnosed with
parkinsonism, dyskinesia, or dystonia (ICD-9-CM 332.0, 332.1,
333.90, 333.99, 333.7, and 333.8) before the index date. In ad-
dition, patients who used fz and cz simultaneously (n = 1016)
were excluded.
Definition of outcomes
Drug-related EPSEs was defined as a diagnosis of parkinsonism,
dyskinesia, or symptomatic dystonia (ICD-9-CM 332.0, 332.1,
333.90, 333.99, 333.7, and 333.8) from the index date to
3 months after stopping either fz or cz [8].
To determine the hazard ratio of extrapyramidal symptoms,
a control group matched by sex, age, and duration of
follow-up was included in the analysis (exposure: control
group = 1:2). Control subjects were excluded due to fulfill-
ment of the exclusion criteria listed above. Five thousand six
hundred three patients were excluded from the study because
there were no suitable control individuals. The potential con-
founders included sex, age, low income, urbanization, and
antipsychotics usage 2 years before the index date (anatomical
therapeutic chemical code N05A), co-morbidities (DM,
ICD-9-CM: 250), chronic kidney disease (CKD, ICD-9-CM:
585), severe liver dysfunction (ICD-9-CM: 572.2, 571.5,
572.2–572.4), history of essential tremor (ICD-9-CM:
333.1), history of other movement disorders (ICD-9-CM:
333.2, 333.3, 333.5, 333.6), and cardiovascular disease
(ICD-9-CM: 410–414, 433, 444)).
Statistical analysis
Data were analyzed using the SAS software. ANOVA
was used to compare the mean difference among groups
for continuous variables while chi-square test was used
for nominal variables. The hazards ratio (HR) and 95%
confidence interval (CI) were estimated using the Cox
proportional hazard model. A P value < 0.05 was con-
sidered statistically significant.
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Results
Table 1 shows basic characteristics of study subjects. In the final
analysis, 26,133 and 7186 individuals were found to have been
prescribed fz or cz, respectively. The matched controls involved
66,638 participants. The incidence rates of fz- and cz-induced
EPSEs were 21.03 and 10.3 per 10,000 person-months, respec-
tively (Table 2). Figure 1 shows the cumulative incidence pro-
portion of the EPSEs. Both fz and cz patients had a higher cu-
mulative incidence of EPSEs than their control individuals
(Fig. 1 a, b, p < 0.001). Patients who were prescribed fz had a
higher cumulative incidence than those who were prescribed cz
(Fig. 1 c, p < 0.001). The incidences of EPSEs in both treatment
groups were higher in the second than the first year of exposure
(i.e., 45.59 vs 18.62 per 10,000 person-months for fz; 13.89 vs
9.41 per 10,000 person-months for cz). The incidence rates of
parkinsonism or dystonia/dyskinesia are listed in supplementary
Table 1. Because many patients had antipsychotics or
metoclopramide concomitantly, the risk of cz- or fz-related
EPSEs might have been overestimated. A sensitivity analysis
which excluded patients concomitantly taking antipsychotics,
reserpine, or metoclopramide with cz or fz showed that the inci-
dence rates of fz (n = 10,020) and cz (n = 2567) induced EPSEs
were 13.05 (10.74–15.86) and 8.10 (5.04–13.04) per 10,000
person-months.
Table 3 shows the HRs for parkinsonism, dyskinesia, or dys-
tonia after exposure to drugs. After adjusting for age, sex, in-
come, urbanization, baseline antipsychotic use, and other comor-
bidities, theHRs for EPSEs among patients whowere exposed to
fz and cz were 8.03 (95%CI 6.55–9.84) and 3.41 (95%CI 2.50–
Table 1 Basic characteristics of
the study participants Flunarizine Cinnarizine Control p value
N 26,133 7186 66,638
Initial age 60.94 ± 10.23 62.29 ± 10.16 61.23 ± 10.23 <.0001
Sex 0.56
Male 9449(36.16%) 2549(35.47%) 23,996(36.01%)
Female 16,684(63.84%) 4637(64.53%) 42,642(63.99%)
Low income <.0001
No 25,891(99.07%) 7135(99.29%) 66,231(99.39%)
Yes 242(0.93%) 51(0.71%) 407(0.61%)
Urbanization <.0001
Urban 14,905(57.04%) 4185(58.24%) 41,320(62.01%)
Normal 8026(30.71%) 1994(27.75%) 18,693(28.05%)
Rural 3202(12.25%) 1007(14.01%) 6625(9.94%)
Comorbidity at baseline
CKD 584(2.23%) 180(2.5%) 1075(1.61%) <.0001
Severe liver dysfunction 424(1.62%) 107(1.49%) 766(1.15%) <.0001
Essential tremor history 139(0.53%) 40(0.56%) 131(0.20%) <.0001
Other movement disorder 64(0.24%) 19(0.26%) 56(0.08%) <.0001
DM 5888(22.53%) 1738(24.19%) 9936(14.91%) <.0001
CVD 7419(28.39%) 1985(27.62%) 9347(14.03%) <.0001
Medication used before baseline
Antipsychotic 2411(9.23%) 541(7.53%) 1796(2.7%) <.0001
N number, CKD chronic kidney disease, DM diabetes mellitus, CVD cardiovascular disease
Table 2 Incidence rate of
parkinsonism, dyskinesia, or












All period 436 21.03 (19.15–23.1) 61 10.30 (8.02–13.24) 127 2.36 (1.99–2.81)
Within
1 year
301 18.62 (16.63–20.85) 41 9.41 (6.93–12.78) 92 2.23 (1.82–2.74)
From 1 to
2 years
102 45.59 (37.55–55.35) 9 13.89 (7.23–26.69) 13 2.21 (1.28–3.80)
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4.63), respectively. Table 4 shows the HRs for parkinsonism,
dyskinesia, or dystonia for different periods. The risk for
EPSEs among subjects who took fz was significantly higher in
the second (HR = 18.55, 95%CI 10.32–33.35) than the first year
(HR = 7.82, 95% CI 6.17–9.93).
Discussion
To our knowledge, there are few epidemiologic studies focus-
ing on fz- and cz-induced EPSEs. The incidence rates of
EPSEs in patients who took fz and cz were 21.03 and 10.3
per 10,000 person-months, respectively. Patients who took fz
and cz were 8.03 and 3.41 times more likely to develop these
symptoms. Previously, Fabinai et al. created a point preva-
lence analysis including 26 patients and found that 50% of
chronic fz and cz users had EPSEs [12].
According to reports from Negrotti [8] and Martí-Masso
[5] et al., the diagnosis of fz or cz induced parkinsonism
should exclude other causes including other offending drugs.
For this reason, we performed a sensitivity analysis which
excluded patients concomitantly taking antipsychotics,
reserpine, or metoclopramide with cz or fz. The incidence
rates of fz- and cz-induced EPSEs were 13.05 and 8.10 per
10,000 person-months. The risks for EPSEs were higher
among subjects who took fz (HR = 10.59, 95% CI = 7.36–
15.22) and cz (HR = 5.49, 95% CI = 3.11–9.70) than their
matched control individuals. We did not use the population of
sensitivity analysis as our main result because of the following
reasons. First, the NHIRD does not contain clinical data;
therefore, we could not clarify distinctly which drug was the
major cause of EPSEs. More than half of the patients were
concomitantly treated with either antipsychotics or
metoclopramide and fz or cz. Further investigations are re-
quired to understand the interactions between these drugs.
Second, the control group may have selection bias when
restricting all these medications. To avoid such biases and to
eliminate the influence of antipsychotics, adjustments were
made for baseline antipsychotic use.
In this study, the fz users had a higher risk of developing
EPSEs than the cz individuals. Fz and cz both block striatal
dopamine D2 receptors at clinically used doses [11]. Loss of
tyrosine hydroxylase in monoaminergic presynaptic neuron
leading to dopamine deletion might also be responsible for
Fig. 1 Kaplan-Meier plot of cumulative incidence proportion of parkinsonism or dyskinesia/dystonia by groups
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these side effects [4, 5, 8]. Since fz is 2.5 to 10 times more
potent than cz [10], it is no surprise that the risk of EPSEs was
2 to 3 times higher in subjects who took fz.
The incidence of EPSEs 1–2 years after fz prescription
(45.59 per 10,000 person-months) was significantly higher
than that within the first year (18.62 per 10,000
person-months). The HR increased from 7.82 (95% CI
6.17–9.93) to 18.55 (95% CI 10.32–33.35) among subjects
who took fz for more than 1 year. However, this was not
obvious in cz individuals. In Fig. 1, the risk of fz-induced
extrapyramidal side effects rose rapidly 2–3 years after the
drug exposure. Previous literatures have reported a positive
relationship between the duration of fz or cz use and the onset
of parkinsonism [12, 13]. The present study has strengthened
this concept and has also demonstrated the differences that
exist between fz and cz. Potential benefits and risks should
be weighed when considering long-term use of these calcium
channel blockers.
This study has several limitations. First, the NHIRD does
not contain information about clinical examination. This study
design may have included patients with clinical presentations
of parkinsonism who have never sought medical advice. In
addition, some authors included clinical improvement after
drug withdrawal as one of the diagnostic criteria of DIP [5].
However, such information was not also available in the
NHIRD. However, more researchers found that patients did
not fully recover after being exposed to cz and fz [8, 14].
Diseases that may cause parkinsonism or dystonia were ex-
cluded from this study. Adjustments were made for possible
confounders such as antipsychotic use. Second, patients with a
diagnosis of Parkinson’s disease or Parkinson plus syndrome
might have been included in the analysis since ICD-9-CM
codes 332.0 and 332.1 were considered as outcomes.
However, according to previous studies, it is hard to distin-
guish between fz- or cz-induced parkinsonism and idiopathic
Parkinson’s disease (IPD) based on clinical presentations
[3–6, 8]. One report showed that 43% patients with fz- or
cz-induced parkinsonism had a clinical pattern similar to
IPD patients. Dopaminergic treatment was also effective in
patients with fz- or cz-induced parkinsonism [15].
Furthermore, more evidence supports that patients with fz-
or cz-induced parkinsonism were not fully recovered after
stopping medications. In addition, some ultimately developed
IPD [5, 8]. In this study, ICD-9-CM codes for Parkinson’s
disease were included into analysis considering that fz- or
cz-induced parkinsonism may be misclassified as IPD.
Third, the incidence of akathisia, one of the EPSEs induced
by fz or cz [12, 14] could not be obtained. There is no specific
Table 3 Cox regression analysis to estimate the hazard ratios of
parkinsonism, dyskinesia, or dystonia
HR 95% C.I. p value
Intervention (ref: control)
Flunarizine 8.03 6.55–9.84 <.0001
Cinnarizine 3.41 2.50–4.63 <.0001
Sex (ref: Female)
Male 0.94 0.79–1.10 0.42
Age (per 1 year) 1.06 1.05–1.07 <.0001
Low income (ref: No)
Yes 1.67 0.92–3.03 0.094
Urbanization (ref: Urban)
Normal 1.11 0.94–1.32 0.219
Rural 0.88 0.69–1.13 0.31
Comorbidity at baseline
(ref: Without)
CKD 1.31 0.87–1.98 0.20
Severe liver dysfunction 0.40 0.15–1.08 0.071
Essential tremor history 6.14 3.91–9.62 <.0001
Other movement disorders 3.97 1.64–9.58 0.002
DM 1.14 0.95–1.36 0.16
CVD 1.33 1.13–1.58 0.0008
Medication used before baseline
(ref: No)
Antipsychotic 1.82 1.44–2.31 <.0001
CKD chronic kidney disease, DM diabetes mellitus, CVD cardiovascular
disease
Table 4 Cox regression model to
estimate the hazard ratios of
parkinsonism, dyskinesia, or
dystonia by groups and
observation period
Flunarizine Cinnarizine
HRa (95% C.I.) p value HRa (95% C.I.) p value
All period (n = 99,957) 8.03 (6.55–9.84) <.0001 3.41 (2.50–4.63) <.0001
Within 1 year (n = 99,957) 7.82 (6.17–9.93) <.0001 3.45 (2.38–5.00) <.0001
From 1 to 2 years (N = 13,116) 18.55 (10.32–33.35) <.0001 4.95 (2.11–11.62) 0.0002
Adjusted for age, sex, low-income household, urbanization, comorbidities (chronic kidney disease, severe liver
dysfunction, history of essential tremor or other movement disorder, and cardiovascular disease), and antipsy-
chotic use at baseline
HR hazard ratio
a Reference group is control group
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ICD-9-CM code for akathisia. Most patients with akathisia
had concomitant parkinsonian symptoms [12]; therefore, the
incidence could not have been underestimated in this study.
In conclusion, cz and fz significantly increased the risk of
extrapyramidal symptoms. Potential risks should be weighed
when considering long-term use of these drugs.
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